舒尼替尼可对复发性和进展性非典型脑膜瘤和间变性脑膜瘤有效

关键信息

该研究纳入36例高级别脑膜瘤频繁复发需行手术和放射治疗的患者，并应用舒尼替尼治疗。仅2例患者对该疗法产生客观应答，不过实现6个月无进展生存期的患者比例为42%，即该研究达到了其主要终点。

作者认为，舒尼替尼起效的这种证据值得进行进一步的随机试验研究。

TAKE-HOME MESSAGE

In this study, 36 patients with high-grade meningioma refractory to surgery and radiotherapy were treated with sunitinib. Only 2 patients had an objective response to therapy, but the 6-month progression-free survival rate was 42%, thereby meeting the primary endpoint of the study.

– Richard Bambury, MD

Neuro-oncology

Phase II Trial of Sunitinib for Recurrent and Progressive Atypical and Anaplastic Meningioma

Neuro-oncology 2014 Aug 06;[EPub Ahead of Print], TJ Kaley, P Wen, D Schiff, K Ligon, S Haidar, S Karimi, AB Lassman, CP Nolan, LM DeAngelis, I Gavrilovic, A Norden, J Drappatz, EQ Lee, B Purow, SR Plotkin, T Batchelor, LE Abrey, A Omuro

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

This abstract is available on the publisher's site.

Access this abstract now

Copyright © 2014 Elsevier Inc. All rights reserved.

独家授权，未经许可，请勿转载。